JSPRInvestor•globenewswire•
Jasper Therapeutics to Present at Upcoming Investor Conferences
Sentiment:Negative (20)
Summary
REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate in the following upcoming investor conferences in September:
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 27, 2025 by globenewswire